Nuvectis Pharma Inc (NVCT) Stock Price, Quote & News

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trial for the treatment of patients with platinum-resistant ARID1a-mutated ovarian carcinoma. The company is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trial that inhibits th...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 614 3150

Website: www.nuvectis.com

Address:

1 Bridge Plaza, Suite 275, Fort Lee, United States

UNLV Aug. 15 at 2:28 PM

$NVCT I'm big Nuvectis Pharma tailing insider action especially Charles continued buying. $OPEN got my action tailing Paul Tudor Jones and Anthony Pompliano don't just follow the money follow...follow the smart money

0 · Reply

biospeculator Aug. 12 at 7:55 PM

$NVCT An institution with more money and better due diligence than myself paid $8-$8.5 per share for 1.6M shares just before the release of the NXP800 results because they were afraid of paying more if the results were good. We now have the opportunity to pay 20% less. Hmmmmm.....I did!

0 · Reply

F4651110 Aug. 12 at 3:43 PM

$NVCT anyone joined the call, any feedback?

2 · Reply

biospeculator Aug. 12 at 2:05 PM

$NVCT Phase 1b begins. New Truffle Pig's thesis is that institutional and hedge fund buying has begun and will continue despite the low float, I agree with this thesis. Simply put, the institutions are under invested. With an upside of 20x(my opinion) or 30x-40x (Truffle Pig) we have plenty of upside during this accumulation period, imo. GLTA

1 · Reply

AmateurHourGR Aug. 12 at 10:59 AM

$NVCT https://nuvectis.com/press-release-view/

0 · Reply

UNLV Aug. 8 at 7:05 PM

$NVCT 800 failure widening quarterly loss double previous quarter and pessimism around 12M dilution alongside market makers taking out Stop/Loss orders $6 gives best entry since February offering. WAITING for better entry will get you PUNKED and buying higher

0 · Reply

BioTrade2 Aug. 8 at 6:09 PM

$NVCT “this better not be the next XAIR” -Charles. That’s what he is probably thinking right now.

2 · Reply

WallStWireAds Aug. 7 at 6:40 PM

$NVCT

0 · Reply

WallStWireAds Aug. 7 at 6:40 PM

$NVCT

0 · Reply

biospeculator Aug. 7 at 2:50 PM

$NVCT Technical analysis imo places $4.5-$5 as a possible target. My current avg. is $6.2. Anything under $5 and I will double my position. GLTA

0 · Reply

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Aug 5, 2025, 7:30 AM EDT - 12 days ago

Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights

Jul 31, 2025, 7:45 AM EDT - 17 days ago

Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study

May 16, 2025, 4:35 PM EDT - 3 months ago

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 8:00 AM EDT - 3 months ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 4:25 PM EDT - 3 months ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Mar 14, 2025, 8:00 AM EDT - 5 months ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Feb 7, 2025, 8:30 AM EST - 6 months ago

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter's Over-Allotment Option

Feb 6, 2025, 2:00 PM EST - 6 months ago

Nuvectis: Additional Data In Q2 Of 2025 Could Allow It To Stage A Comeback

Feb 5, 2025, 9:01 AM EST - 6 months ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

Feb 4, 2025, 4:05 PM EST - 6 months ago

Nuvectis Pharma Announces Proposed Public Offering of Common Stock

Nov 14, 2024, 2:23 PM EST - 9 months ago

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug

Nov 5, 2024, 7:00 AM EST - 10 months ago

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

Oct 28, 2024, 8:21 AM EDT - 10 months ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

DRUG

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers

Aug 6, 2024, 8:28 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights

May 16, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

May 7, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights

Apr 8, 2024, 8:30 AM EDT - 1 year ago

Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines

Mar 19, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 14, 2024, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Mar 5, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights

Feb 9, 2024, 8:32 AM EST - 1 year ago

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Feb 9, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Jan 3, 2024, 8:00 AM EST - 1 year ago

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 1 year ago

Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

Sep 25, 2023, 7:30 PM EDT - 2 years ago

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

Sep 6, 2023, 8:03 AM EDT - 2 years ago

Nuvectis: Early Stage Company That's Low On Cash

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

Aug 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

Aug 9, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

May 15, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

Apr 27, 2023, 10:14 AM EDT - 2 years ago

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

Mar 17, 2023, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

Mar 10, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

Mar 7, 2023, 8:00 AM EST - 2 years ago

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

Dec 1, 2022, 8:00 AM EST - 2 years ago

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Nov 8, 2022, 8:00 AM EST - 3 years ago

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

Oct 18, 2022, 8:00 AM EDT - 3 years ago

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 3, 2022, 4:30 PM EDT - 3 years ago

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

Sep 28, 2022, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces Formation of a Scientific Advisory Board

Sep 13, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma

Sep 7, 2022, 8:30 AM EDT - 3 years ago

Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences

Aug 5, 2022, 8:00 AM EDT - 3 years ago

Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights

UNLV Aug. 15 at 2:28 PM

0 · Reply

biospeculator Aug. 12 at 7:55 PM

0 · Reply

F4651110 Aug. 12 at 3:43 PM

$NVCT anyone joined the call, any feedback?

2 · Reply

biospeculator Aug. 12 at 2:05 PM

1 · Reply

AmateurHourGR Aug. 12 at 10:59 AM

$NVCT https://nuvectis.com/press-release-view/

0 · Reply

UNLV Aug. 8 at 7:05 PM

0 · Reply

BioTrade2 Aug. 8 at 6:09 PM

$NVCT “this better not be the next XAIR” -Charles. That’s what he is probably thinking right now.

2 · Reply

WallStWireAds Aug. 7 at 6:40 PM

$NVCT

0 · Reply

WallStWireAds Aug. 7 at 6:40 PM

$NVCT

0 · Reply

biospeculator Aug. 7 at 2:50 PM

$NVCT Technical analysis imo places $4.5-$5 as a possible target. My current avg. is $6.2. Anything under $5 and I will double my position. GLTA

0 · Reply

UNLV Aug. 6 at 6:41 PM

$NVCT I'm deep the stock around insider buying. Those doing fundamentals may understand recent capital raise around new added indications for 900 going into 1b

0 · Reply

biospeculator Aug. 6 at 11:50 AM

$NVCT OK some quick thoughts. Below is a bunch of spam nonsense. Enough of that. Second, we now know why Wrongwright lowered their target. NVCT due to high demand was able to utilize their ATM, a cheaper and more efficient method of raising capital while controlling who bought the shares and avoiding the costs or games of these secondary capital firms who first short any company looking to do a secondary and manipulating the shares. NVCT is protecting the shareholders who are primarily insiders.

1 · Reply

d_risk Aug. 5 at 5:20 PM

$NVCT - Nuvectis Pharma Inc. Common Stock - 10Q - Updated Risk Factors NVCT’s 10-Q highlights intensified risks tied to its early-stage status, clinical and regulatory uncertainties for NXP900/NXP800, funding needs with dilution potential, supply chain and trade policy impacts, complex IP and licensing challenges, reliance on third parties, and evolving regulatory and market acceptance hurdles. #Biotechnology #SupplyChain #FundingDilution #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/NVCT/10-Q/2025-08-05

0 · Reply

d_risk Aug. 5 at 1:35 PM

0 · Reply

essiepaul Aug. 4 at 10:22 PM

$NVCT Ah Wainwrong in the house again. Takes it from $15 to $10 and she goes up. Guy is all over the map. Last yr he had a $20 PT

0 · Reply

tasha655 Aug. 4 at 2:55 PM

$NVCT buy below 7 and sell at 10

0 · Reply

JarvisFlow Aug. 4 at 2:50 PM

HC Wainwright & Co. has updated their rating for Nuvectis Pharma ( $NVCT ) to Buy with a price target of 10.

0 · Reply

RideLikABravo Aug. 3 at 8:21 PM

$NVCT $XFOR 🧐🤔👌 https://www.insidermonkey.com/blog/why-these-15-healthcare-stocks-are-surging-in-2025-1518414/?singlepage=1

1 · Reply

biospeculator Aug. 3 at 5:00 PM

$NVCT Final post until 1b results. My target is $40 which represents a 1B market valuation with some minor ATM dilution if available or small secondary upon results. A phase II trial with endpoints being met imo could see a $80-$100 buyout price. These are my thoughts and not to be used as investment advice. I am long and from time to time will trade around my position. I look forward to posting again when 1b results are released. GLTA

1 · Reply

biospeculator Aug. 2 at 6:10 PM

$NVCT https://www.nasdaq.com/press-release/nuvectis-pharmas-nxp900-could-revolutionary-cancer-inactivator-transform-oncology

1 · Reply

biospeculator Aug. 2 at 5:26 PM

$NVCT https://www.stocktitan.net/news/NVCT/nuvectis-pharma-announces-a-new-publication-of-a-research-study-i1nhbinqmbqz.html I also play pickleball with a doctor working with Cleveland Clinic. I am LONG NVCT

2 · Reply

UNLV Aug. 1 at 6:57 PM

$NVCT 800 trials, tiny 12 patient trials at that , did absolutely nothing to dampen company prospects. Biotechs large and small run simultaneous trials on multiple drug all the time. Trials much larger than 12,patient trials around 800. I’m deep the stock around Charles continued insider buying and small market cap…nothing else

1 · Reply

Market Cap	163.69M
Revenue (ttm)	0.00
Net Income (ttm)	-19.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	51,200
Avg Vol	184,538
Day's Range	N/A - N/A
Shares Out	25.46M
Stochastic %K	38%
Beta	-0.26
Analysts	Strong Sell
Price Target	$18.00